The 9p21 Rs 1333040 polymorphism is associated with coronary microvascular obstruction in ST-segment elevation myocardial infarction treated by primary angioplasty.


Journal

European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 7 10 2017
medline: 21 4 2020
entrez: 7 10 2017
Statut: ppublish

Résumé

Microvascular obstruction (MVO) after primary percutaneous coronary intervention (pPCI) leads to higher incidence of both early and late complications. A number of single nucleotide polymorphisms in 9p21 chromosome have been shown to affect angiogenesis in response to ischaemia. In particular, Rs1333040 with its three genotypic vriants C/C, T/C and T/T might influence the occurrence of MVO after pPCI. We enrolled ST-elevation myocardial infarction (STEMI) patients undergoing pPCI. The Rs1333040 polymorphism was evaluated by polymerase chain reaction-restriction fragment length polymorphism using restriction endonucleases (Bsml). Two expert operators unaware of the patients' identity performed the angiographic analysis; collaterals were assessed applying Rentrop's classification. Angiographic MVO was defined as a post-pPCI Thrombolysis In Myocardial Infarction (TIMI)<3 or TIMI 3 with myocardial blush grade 0 or 1, whereas electrocardiographic MVO was defined as ST segment resolution <70% one hour after pPCI. Among our 133 STEMI patients (mean age 63 ± 11 years, men 72%), 35 (26%) and 53 (40%) respectively experienced angiographic or electrocardiographic MVO. Angiographic and electrocardiographic MVO were different among the three variants ( Rs1333040 polymorphism genetic variants portend different MVO incidence. In particular, T/T genotype is related to angiographic and electrocardiographic MVO and to worse collaterals towards the culprit artery.

Sections du résumé

BACKGROUND BACKGROUND
Microvascular obstruction (MVO) after primary percutaneous coronary intervention (pPCI) leads to higher incidence of both early and late complications. A number of single nucleotide polymorphisms in 9p21 chromosome have been shown to affect angiogenesis in response to ischaemia. In particular, Rs1333040 with its three genotypic vriants C/C, T/C and T/T might influence the occurrence of MVO after pPCI.
METHODS METHODS
We enrolled ST-elevation myocardial infarction (STEMI) patients undergoing pPCI. The Rs1333040 polymorphism was evaluated by polymerase chain reaction-restriction fragment length polymorphism using restriction endonucleases (Bsml). Two expert operators unaware of the patients' identity performed the angiographic analysis; collaterals were assessed applying Rentrop's classification. Angiographic MVO was defined as a post-pPCI Thrombolysis In Myocardial Infarction (TIMI)<3 or TIMI 3 with myocardial blush grade 0 or 1, whereas electrocardiographic MVO was defined as ST segment resolution <70% one hour after pPCI.
RESULTS RESULTS
Among our 133 STEMI patients (mean age 63 ± 11 years, men 72%), 35 (26%) and 53 (40%) respectively experienced angiographic or electrocardiographic MVO. Angiographic and electrocardiographic MVO were different among the three variants (
CONCLUSION CONCLUSIONS
Rs1333040 polymorphism genetic variants portend different MVO incidence. In particular, T/T genotype is related to angiographic and electrocardiographic MVO and to worse collaterals towards the culprit artery.

Identifiants

pubmed: 28984467
doi: 10.1177/2048872617735808
doi:

Substances chimiques

CDKN1A protein, human 0
Cyclin-Dependent Kinase Inhibitor p21 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

703-707

Auteurs

Francesco Fracassi (F)

Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.

Giampaolo Niccoli (G)

Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.

Vincenzo Vetrugno (V)

Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.

Michele Cauteruccio (M)

Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.

Antonino Buffon (A)

Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.

Ilaria Gatto (I)

Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy.

Igor Giarretta (I)

Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy.

Paolo Tondi (P)

Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy.

Roberto Pola (R)

Institute of Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy.

Filippo Crea (F)

Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH